Since ESR1 mutations are potential clinical biomarkers to guide therapeutic decisions, identification of small molecules able to block proliferation of metastatic tumors expressing one prevalent mERα resistant phenotypes may result in counteracting, preventing and/or delaying their occurrence in early disease stage. Here, ESR1 is linked to metastatic neoplasm.